MIST
Milestone Pharmaceuticals Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Milestone Pharmaceuticals Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No thesis.
—
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Annual filing, covered
10-K parsed · Mar 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 20 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Milestone Pharmaceuticals Inc..
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Milestone Pharmaceuticals Inc..
—
—
Largest filed tie
—
Tall tick = annual report · Source: EDGAR
Milestone Pharmaceuticals Inc.
0.78
+0.02 · +2.32%
| Manager | Value | % base | |
|---|---|---|---|
| Pavaki | $12.2M | 18.19% | +0.06% |
| RTW | $10.5M | 15.71% | +23.73% |
| Propel Bio | $10.0M | 14.90% | +80.40% |
| Point72 | $7.3M | 10.85% | +398.41% |
| Simplify | $4.5M | 6.72% | +122.34% |
| Manager | Value | % base | |
|---|---|---|---|
| Pavaki | $12.2M | 18.19% | +0.06% |
| RTW | $10.5M | 15.71% | +23.73% |
| Propel Bio | $10.0M | 14.90% | +80.40% |
| Point72 | $7.3M | 10.85% | +398.41% |
| Simplify | $4.5M | 6.72% | +122.34% |
Expected move
Inputsstraddle ±70.0%
spot 0.76exp Nov 20ATM strike 1ATM straddle 0.63IV 412%